



**Primus Ray
Laboratories**

BOLDENONE UNDECYLENATE 250mg/ml

BOLDENONE UNDECYLENATE 250 – BOLDENONE UNDECYLENATE 250 –
BOLDENONE UNDECYLENATE USP 250mg

Ethyl Oleate q.s.

presented as 10x1ml cartridges per box (250mg/ml)

DESCRIPTION:

BOLDENONE UNDECYLENATE 250 (BOLDENONE UNDECYLENATE 250mg)
is an injectable anabolic preparation. After injection, boldenone undecylenate is
gradually released from the intramuscular depot and subsequently hydrolyzed into
dihydroboldenone.

Boldenone is indicated for Osteoporosis due to androgen deficiency in hypo-
gonadal males. It will also cause the muscle cell to store more nitrogen than
it releases so that a positive nitrogen balance is achieved. A positive nitrogen
balance is synonymous with anabolism and assimilates a larger amount of protein
than usual.

The result is a positive nitrogen balance and the protein building effect that
accompany it. Boldenone Undecylenate 250 is a long acting compound, with the
undecanoate ester (Boldenone Undecylenate) providing this drug a slow release
time of up to three weeks.

Boldenone Undecylenate 250 is approved for the following uses:

- As an anabolic steroid
- Treatment of certain cases of disseminated breast cancer in women
- Osteoporosis due to androgen deficiency in hypogonadal males

Chemical: Boldenone Undecylenate 250mg/ml

Additional Names: Boldenone undec-10-enoate; 17b-[(1-Oxo-10-undecenyl)oxy]-
androsta-1,4-dien-3-one; 17b-Hydroxyandrosta-1,4-dien-3-one 10-undecenoate

Molecular Formula: C₃₀H₄₄O₃

Molecular Weight: 452.67

Melting point: mp 32-35°

Prescription Medicine

Boldenone Undecylenate
Boldenone Undecylenate USP 250 mg
Ethyl Oleate q.s.

DESCRIPTION

Boldenone Undecylenate Injection is an injectable anabolic preparation. After
injection, Boldenone Undecylenate is gradually released from the intramuscular
depot and subsequently hydrolyzed into dihydroboldenone.

INDICATIONS

- As an anabolic steroid.
- Certain cases of disseminated breast cancer in women.
- Osteoporosis due to androgen deficiency in hypogonadal males.

CONTRAINDICATIONS

Not intended for use in children.

Known or suspected prostatic carcinoma and mammary carcinoma in the male.

Not intended for use in female patients other than those with disseminated breast
cancer.

Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal
failure, hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin
excretion, testicular and hepatic carcinoma.

DOSAGE AND DIRECTIONS FOR USE

Boldenone Undecylenate injection should be administered by deep intramuscular
injection.

Adult dose: 75 mg to 150 mg every three weeks.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:

Virilization which appears in sensitive women as hoarseness, acne, hirsutism and
increased libido; in prepubertal boys as an increased frequency of erections and
phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertro-
phy. Hoarseness may be the first symptom of vocal change which may end in a
long-lasting, sometime irreversible deepening of the voice.
Other adverse reactions may include:

Oligospermia and decreased ejaculatory volume.
Suppression of ovarian activity, atrophy of the breasts and endometrial tissue
Amenorrhea and inhibition of spermatogenesis
Water and salt retention

Premature epiphyseal closure
If signs of virilization develop, treatment should be discontinued
Increase in nitrogen retention and skeletal weight
Oedema
Increased vascularity of the skin
Increased growth of the bone
Elderly males may become over stimulated

Patients with the following conditions should be monitored:

Latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or
migraine (or a history of these conditions), since anabolic steroids may induce salt
and fluid retention

Diabetes, since anabolic steroids may improve the glucose tolerance and de-
crease the need for insulin or other antidiabetic drugs

Incomplete stature growth, since anabolic steroids may induce hypercalcemia
and hypercalciuria in these patients

Liver dysfunction

DRUG INTERACTIONS

Liver enzyme-inducing agents may reduce the effects of Boldenone by enhancing
its effects in the liver.

PRESENTATION:

250 mg/ml, 10x1ml cartridges

STORAGE:

Store in a cool dry place (30 C ± 2 C). Protect from light. Warming and rotating the
vial between the palms of the hands will redissolve any crystals that may have
formed during storage at low temperatures.